ReviewGut and liver2025
Endoscopic Resection for Superficial Non-Ampullary Duodenal Epithelial Tumors.
Review in Gut and liver, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Novel Traction-Assisted Endoscopic Resection for Superficial Non-ampullary Duodenal Epithelial Tumors: 15-Year Experience from a Large Tertiary Center.Digestive diseases and sciences · 2026Article
- An Intraductal Papillary Mucinous Neoplasm-Like Lesion Manifesting as a Duodenal Polyp: A Rare Case Report.The Korean journal of helicobacter and upper gastrointestinal research · 2026Article
- Gaining Traction: How Adjustable Clip-and-Rubber Band Traction Improves Duodenal Endoscopic Submucosal Dissection.Digestive diseases and sciences · 2026Article
- Article
- Endoscopic submucosal dissection of duodenal Brunner's gland mass using transpyloric traction wire fixation.VideoGIE : an official video journal of the American Society for Gastrointestinal Endoscopy · 2026Article
- Feasibility of pancreatic duct stent placement before endoscopic submucosal dissection for superficial duodenal neoplasms adjacent to the papilla.Clinical endoscopy · 2026Article
- Laparoscopic and endoscopic cooperative surgery in gastrointestinal tumors: current applications, oncologic considerations, and future directions.Frontiers in oncology · 2026Review
- Recent advancement in size measurement during endoscopy.Clinical endoscopy · 2026Review
- Reply to the comments on 'Utility of underwater endoscopic mucosal resection combined with a protruding anchor by saline injection for superficial non-ampullary duodenal tumors: a retrospective study in Japan'.Clinical endoscopy · 2025Article
- Evaluation of a modified underwater endoscopic mucosal resection technique for duodenal neoplasms: clinical implications and future directions.Clinical endoscopy · 2025Article
- Utility of underwater endoscopic mucosal resection combined with a protruding anchor by saline injection for superficial non-ampullary duodenal tumors: a retrospective study in Japan.Clinical endoscopy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An increasing number of superficial non-ampullary duodenal epithelial tumors (SNADETs) have been detected recently owing to the development of endoscopic imaging technology and increased awareness of this disease. Endoscopic resection is the first-line treatment for SNADETs, with methods including cold snare polypectomy (CSP), conventional endoscopic mucosal resection (cEMR), underwater EMR (uEMR), and endoscopic submucosal dissection (ESD). Here, we review the current status and recent advances in endoscopic resection for SNADETs. Endoscopic resection in the duodenum is more difficult and has a higher risk of adverse events than that in other organs owing to specific anatomical disadvantages. SNADETs ≤10 mm in size are candidates for CSP, cEMR, and uEMR. Among these lesions, suspected carcinoma lesions should not be treated using CSP because of their low curability. cEMR or uEMR is considered for lesions sized 10 to 20 mm, whereas piecemeal EMR or ESD is considered for tumors >20 mm in size. In particular, ESD or surgical resection should be considered for suspected carcinoma lesions >30 mm in size. The treatment plan should be selected on a case-to-case basis, considering the balance between the risk of adverse events and the necessity of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.